LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 74

Search options

  1. Article ; Online: Seroconversion after SARS-CoV-2 mRNA booster vaccine in cancer patients.

    Patelli, Giorgio / Pani, Arianna / Amatu, Alessio / Scaglione, Francesco / Sartore-Bianchi, Andrea

    European journal of cancer (Oxford, England : 1990)

    2022  Volume 167, Page(s) 175–176

    MeSH term(s) COVID-19/prevention & control ; COVID-19 Vaccines/adverse effects ; Humans ; Neoplasms ; RNA, Messenger ; SARS-CoV-2 ; Seroconversion
    Chemical Substances COVID-19 Vaccines ; RNA, Messenger
    Language English
    Publishing date 2022-03-15
    Publishing country England
    Document type Letter ; Research Support, Non-U.S. Gov't ; Comment
    ZDB-ID 82061-1
    ISSN 1879-0852 ; 0277-5379 ; 0959-8049 ; 0964-1947
    ISSN (online) 1879-0852
    ISSN 0277-5379 ; 0959-8049 ; 0964-1947
    DOI 10.1016/j.ejca.2022.02.032
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 456: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 583: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Ongoing Clinical Trials and Future Research Scenarios of Circulating Tumor DNA for the Treatment of Metastatic Colorectal Cancer.

    Roazzi, Laura / Patelli, Giorgio / Bencardino, Katia Bruna / Amatu, Alessio / Bonazzina, Erica / Tosi, Federica / Amoruso, Brunella / Bombelli, Anna / Mariano, Sara / Stabile, Stefano / Porta, Camillo / Siena, Salvatore / Sartore-Bianchi, Andrea

    Clinical colorectal cancer

    2024  

    Abstract: Liquid biopsy using circulating tumor DNA (ctDNA) has emerged as a minimally invasive, timely approach to provide molecular diagnosis and monitor tumor evolution in patients with cancer. Since the molecular landscape of metastatic colorectal cancer (mCRC) ...

    Abstract Liquid biopsy using circulating tumor DNA (ctDNA) has emerged as a minimally invasive, timely approach to provide molecular diagnosis and monitor tumor evolution in patients with cancer. Since the molecular landscape of metastatic colorectal cancer (mCRC) is substantially heterogeneous and dynamic over space and time, ctDNA holds significant advantages as a biomarker for this disease. Numerous studies have demonstrated that ctDNA broadly recapitulates the molecular profile of the primary tumor and metastases, and have mainly focused on the genotyping of RAS and BRAF, that is propaedeutic for anti-EGFR treatment selection. However, ctDNA soon broadened its scope towards the assessment of early tumor response, as well as the identification of drug resistance biomarkers to drive potential molecular actionability. In this review article, we provide an overview of the current state-of-the-art of this methodology and its applications, focusing on ongoing clinical trials that employ ctDNA to prospectively guide treatment in patients with mCRC.
    Language English
    Publishing date 2024-02-16
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2112638-0
    ISSN 1938-0674 ; 1533-0028
    ISSN (online) 1938-0674
    ISSN 1533-0028
    DOI 10.1016/j.clcc.2024.02.001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5798: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 435: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Clinicopathological characterisation of

    Mauri, Gianluca / Patelli, Giorgio / Roazzi, Laura / Valtorta, Emanuele / Amatu, Alessio / Marrapese, Giovanna / Bonazzina, Erica / Tosi, Federica / Bencardino, Katia / Ciarlo, Gabriele / Mariella, Elisa / Marsoni, Silvia / Bardelli, Alberto / Bonoldi, Emanuela / Sartore-Bianchi, Andrea / Siena, Salvatore

    Journal of clinical pathology

    2024  

    Abstract: Background: Methylthioadenosine phosphorylase (MTAP) is an essential metabolic enzyme in the purine and methionine salvage pathway. In cancer, : Methods: Cases with : Results: Findings across the TCGA dataset (N=1363 patients) and our cohort (N= ... ...

    Abstract Background: Methylthioadenosine phosphorylase (MTAP) is an essential metabolic enzyme in the purine and methionine salvage pathway. In cancer,
    Methods: Cases with
    Results: Findings across the TCGA dataset (N=1363 patients) and our cohort (N=508) were consistent. Gene loss was the most common
    Conclusions: MTAP
    Language English
    Publishing date 2024-02-13
    Publishing country England
    Document type Journal Article
    ZDB-ID 80261-x
    ISSN 1472-4146 ; 0021-9746
    ISSN (online) 1472-4146
    ISSN 0021-9746
    DOI 10.1136/jcp-2023-209341
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ud II Zs.139: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: Corrigendum: Case report:

    Mauri, Gianluca / Patelli, Giorgio / Gori, Viviana / Lauricella, Calogero / Mussolin, Benedetta / Amatu, Alessio / Bencardino, Katia / Tosi, Federica / Bonazzina, Erica / Bonoldi, Emanuela / Bardelli, Alberto / Siena, Salvatore / Sartore-Bianchi, Andrea

    Frontiers in oncology

    2023  Volume 13, Page(s) 1147497

    Abstract: This corrects the article DOI: 10.3389/fonc.2022.1030232.]. ...

    Abstract [This corrects the article DOI: 10.3389/fonc.2022.1030232.].
    Language English
    Publishing date 2023-03-28
    Publishing country Switzerland
    Document type Published Erratum
    ZDB-ID 2649216-7
    ISSN 2234-943X
    ISSN 2234-943X
    DOI 10.3389/fonc.2023.1147497
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Case Report:

    Mauri, Gianluca / Patelli, Giorgio / Gori, Viviana / Lauricella, Calogero / Mussolin, Benedetta / Amatu, Alessio / Bencardino, Katia / Tosi, Federica / Bonazzina, Erica / Bonoldi, Emanuela / Bardelli, Alberto / Siena, Salvatore / Sartore-Bianchi, Andrea

    Frontiers in oncology

    2022  Volume 12, Page(s) 1030232

    Abstract: Background: We aim to identify the prevalence and the role of the : Methods: We retrospectively reviewed tumor-based next generation sequencing (NGS) results from mCRC patients screened for enrollment in the GO40872/STARTRK-2 clinical trial between ... ...

    Abstract Background: We aim to identify the prevalence and the role of the
    Methods: We retrospectively reviewed tumor-based next generation sequencing (NGS) results from mCRC patients screened for enrollment in the GO40872/STARTRK-2 clinical trial between July 2019 and March 2021. Then, in patients harboring microsatellite stable (MSS)
    Results: A total of 246 mCRC patients were screened. Most of them, 215/220 (97.7%), were diagnosed with MSS mCRC and 112/215 (52.1%) with MSS,
    Conclusion: We verified in a clinical real-world setting that
    Language English
    Publishing date 2022-11-07
    Publishing country Switzerland
    Document type Case Reports
    ZDB-ID 2649216-7
    ISSN 2234-943X
    ISSN 2234-943X
    DOI 10.3389/fonc.2022.1030232
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: NTRK

    Amatu, Alessio / Sartore-Bianchi, Andrea / Siena, Salvatore

    ESMO open

    2016  Volume 1, Issue 2, Page(s) e000023

    Abstract: The tropomyosin receptor kinase (Trk) receptor family comprises 3 transmembrane proteins referred to as Trk A, B and C (TrkA, TrkB and TrkC) receptors that are encoded by the NTRK1, NTRK2 and NTRK3 genes, respectively. These receptor tyrosine kinases are ...

    Abstract The tropomyosin receptor kinase (Trk) receptor family comprises 3 transmembrane proteins referred to as Trk A, B and C (TrkA, TrkB and TrkC) receptors that are encoded by the NTRK1, NTRK2 and NTRK3 genes, respectively. These receptor tyrosine kinases are expressed in human neuronal tissue and play an essential role in the physiology of development and function of the nervous system through activation by neurotrophins. Gene fusions involving NTRK genes lead to transcription of chimeric Trk proteins with constitutively activated or overexpressed kinase function conferring oncogenic potential. These genetic abnormalities have recently emerged as targets for cancer therapy, because novel compounds have been developed that are selective inhibitors of the constitutively active rearranged proteins. Developments in this field are being aided by next generation sequencing methods as tools for unbiased gene fusions discovery. In this article, we review the role of NTRK gene fusions across several tumour histologies, and the promises and challenges of targeting such genetic alterations for cancer therapy.
    Language English
    Publishing date 2016-03-18
    Publishing country England
    Document type Review ; Journal Article
    ISSN 2059-7029
    ISSN 2059-7029
    DOI 10.1136/esmoopen-2015-000023
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  7. Article: Superior vena cava Candida krusei septic thrombophlebitis in an ARDS patient on ECMO, with an unusual late complication.

    Iskandar, Elizabeth / Cavanna, Caterina / Mollaschi, Eva Maria Giada / Trani, Ruben Mattia / Mojoli, Francesco / Amatu, Alessandro

    The new microbiologica

    2023  Volume 46, Issue 1, Page(s) 90–94

    Abstract: Candida-related bloodstream infections (BSIs) represent a severe condition associated with health care in the critical patient, with an increasing incidence of Candida non-albicans species. These infections could lead to several and unusual complications ...

    Abstract Candida-related bloodstream infections (BSIs) represent a severe condition associated with health care in the critical patient, with an increasing incidence of Candida non-albicans species. These infections could lead to several and unusual complications in high-risk patients due to various factors, including a prolonged hospital stay and invasive medical interventions. Here we report a case of a Candida krusei septic thrombophlebitis in an ARDS patient admitted to the ICU, complicated by a late onset prostatic abscess. To our knowledge, our patient represents the first reported case of a prostatic abscess due to Candida krusei treated with pharmacological therapy alone.
    MeSH term(s) Humans ; Abscess ; Extracorporeal Membrane Oxygenation ; Vena Cava, Superior ; Candida albicans ; Candidiasis/complications ; Candidiasis/drug therapy ; Respiratory Distress Syndrome/etiology ; Respiratory Distress Syndrome/therapy
    Language English
    Publishing date 2023-02-09
    Publishing country Italy
    Document type Case Reports ; Journal Article
    ZDB-ID 756168-4
    ISSN 1121-7138 ; 0391-5352
    ISSN 1121-7138 ; 0391-5352
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 2267: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Circulating Tumor DNA to Drive Treatment in Metastatic Colorectal Cancer.

    Patelli, Giorgio / Mauri, Gianluca / Tosi, Federica / Amatu, Alessio / Bencardino, Katia / Bonazzina, Erica / Pizzutilo, Elio Gregory / Villa, Federica / Calvanese, Gabriele / Agostara, Alberto Giuseppe / Stabile, Stefano / Ghezzi, Silvia / Crisafulli, Giovanni / Di Nicolantonio, Federica / Marsoni, Silvia / Bardelli, Alberto / Siena, Salvatore / Sartore-Bianchi, Andrea

    Clinical cancer research : an official journal of the American Association for Cancer Research

    2023  Volume 29, Issue 22, Page(s) 4530–4539

    Abstract: In the evolving molecular treatment landscape of metastatic colorectal cancer (mCRC), the identification of druggable alterations is pivotal to achieve the best therapeutic opportunity for each patient. Because the number of actionable targets is ... ...

    Abstract In the evolving molecular treatment landscape of metastatic colorectal cancer (mCRC), the identification of druggable alterations is pivotal to achieve the best therapeutic opportunity for each patient. Because the number of actionable targets is expanding, there is the need to timely detect their presence or emergence to guide the choice of different available treatment options. Liquid biopsy, through the analysis of circulating tumor DNA (ctDNA), has proven safe and effective as a complementary method to address cancer evolution while overcoming the limitations of tissue biopsy. Even though data are accumulating regarding the potential for ctDNA-guided treatments applied to targeted agents, still major gaps in knowledge exist as for their application to different areas of the continuum of care. In this review, we recapitulate how ctDNA information could be exploited to drive different targeted treatment strategies in mCRC patients, by refining molecular selection before treatment by addressing tumor heterogeneity beyond tumor tissue biopsy; longitudinally monitoring early-tumor response and resistance mechanisms to targeted agents, potentially leading to tailored, molecular-driven, therapeutic options; guiding the molecular triage towards rechallenge strategies with anti-EGFR agents, suggesting the best time for retreatment; and providing opportunities for an "enhanced rechallenge" through additional treatments or combos aimed at overcoming acquired resistance. Besides, we discuss future perspectives concerning the potential role of ctDNA to fine-tune investigational strategies such as immuno-oncology.
    MeSH term(s) Humans ; Circulating Tumor DNA/genetics ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/genetics ; Colorectal Neoplasms/pathology ; Colonic Neoplasms/drug therapy ; Rectal Neoplasms/drug therapy ; Antineoplastic Agents/therapeutic use ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/therapeutic use
    Chemical Substances Circulating Tumor DNA ; Antineoplastic Agents ; Biomarkers, Tumor
    Language English
    Publishing date 2023-07-11
    Publishing country United States
    Document type Review ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1225457-5
    ISSN 1557-3265 ; 1078-0432
    ISSN (online) 1557-3265
    ISSN 1078-0432
    DOI 10.1158/1078-0432.CCR-23-0079
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4223: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article: The Evolutionary Landscape of Treatment for

    Mauri, Gianluca / Bonazzina, Erica / Amatu, Alessio / Tosi, Federica / Bencardino, Katia / Gori, Viviana / Massihnia, Daniela / Cipani, Tiziana / Spina, Francesco / Ghezzi, Silvia / Siena, Salvatore / Sartore-Bianchi, Andrea

    Cancers

    2021  Volume 13, Issue 1

    Abstract: ... ...

    Abstract The
    Language English
    Publishing date 2021-01-04
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers13010137
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article: Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study.

    Amatu, Alessio / Mauri, Gianluca / Tosi, Federica / Bencardino, Katia / Bonazzina, Erica / Gori, Viviana / Ruggieri, Lorenzo / Arena, Sabrina / Bardelli, Alberto / Marsoni, Silvia / Siena, Salvatore / Sartore-Bianchi, Andrea

    Cancers

    2022  Volume 14, Issue 5

    Abstract: Background: oxaliplatin with fluoropyrimidine is a "mainstay" regarding the upfront treatment of metastatic colorectal cancer (mCRC). In contrast, the efficacy and safety of oxaliplatin-based regimens in late-care settings have been poorly reported.: ... ...

    Abstract Background: oxaliplatin with fluoropyrimidine is a "mainstay" regarding the upfront treatment of metastatic colorectal cancer (mCRC). In contrast, the efficacy and safety of oxaliplatin-based regimens in late-care settings have been poorly reported.
    Methods: we identified a real-world mCRC patient cohort who were re-treated with oxaliplatin, and in which clinicopathological features were retrospectively analyzed to identify efficacy-predictive determinants (RETROX-CRC study).
    Results: of 2606 patients, 119 fulfilled the eligibility criteria. Oxaliplatin retreatment response rate (RR) and disease control rate (DCR) were 21.6% (CI 14.4-31.0%), and 57.8% (CI 47.7-67.4). A trend towards better RR and DCR was observed among patients who had first oxaliplatin in an adjuvant setting; a poorer outcome was observed if two or more intervening treatments were delivered. Median progression-free survival (PFS) was 5.1 months (95%CI 4.3-6.1), reducing to 4.0 months (95%CI 3.07-5.13) if oxaliplatin was readministered beyond third-line (HR 2.02; 1.25-3.25;
    Conclusions: oxaliplatin retreatment produced further RR in around one-fifth of patients and DCR 57.8%. Efficacy decreased in more pre-treated patients and around one-third of patients discontinued treatment due to adverse events. Translational studies improving patient selection are warranted.
    Language English
    Publishing date 2022-02-25
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers14051197
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top